iShares Bitcoin Trust vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Bitcoin Trust trades at $37.65, while Regeneron Pharmaceuticals Inc trades at $674.72 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while iShares Bitcoin Trust pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| IBIT | REGN | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $71.29 | $812.27 |
52-Week Low | $33.29 | $545.46 |
Market Cap | — | $70.47B |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $36.89, up 1.49% with neutral technical signals. The stock shows mixed momentum with bearish moving averages but neutral oscillators. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing Fidelity's competing fund. The ETF faces headwinds from significant outflows in June 2026 but maintains institutional interest as a preferred Bitcoin exposure vehicle.
Outlook remains cautious amid Bitcoin market volatility and ETF outflow pressures. Investment opportunity lies in IBIT's dominant market position and institutional adoption, balanced against cryptocurrency market risks and competitive ETF landscape. Key risks include Bitcoin price sensitivity and regulatory uncertainty affecting fund flows.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Trailing returns across standard periods
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →